

Change Summary of all Information Collection Data Element and Response Changes

Collection Domain Sub-		required if	Collection may be requested	Element (if	Current Information Collection Data Element Response Option(s)	Information Collection update:	Proposed Information Collection Data Element (if applicable)		Rationale for Information Collection Update
Pre-					вмт			BMT	Be consistent with current clinical
Transplant	Clinical Trial				CTN,COG,Other,PIDTC	Change/Clarification of		CTN,COG,Other,PIDTC,RCI	landscape, improve transplant outcome
Essential Data	Participants	yes	no	Study Sponsor	,RCI BMT,USIDNET	Response Options	Study Sponsor	BMT,USIDNET, PedAL	data
Pre- Transplant	Allogeneic Donors	VAS	yes	Non-NMDP unrelated donor ID:	open text	Change/Clarification of Information Requested	Non NMDP unrelated donor-	open text	Capture data accurately
Pre- Transplant	Autologous			What agents were used to mobilize the	G-CSF (filgrastim, Neupogen), Pegylated G-CSF (pegfilgrastim, Neulasta), Plerixafor (Mozobil), Combined with chemotherapy, Anti-CD20 (rituximab,	Change/Clarification of	What agents were used to mobilize the autologous recipient for this HCT? (check all that	G-CSF (TBO-filgrastim, filgrastim, Granix, Neupogen), GM-CSF (sargramostim, Leukine), Pegylated G-CSF (pegfilgrastim, Neulasta), Plerixafor (Mozobil), Combined with chemotherapy, Anti-CD20 (rituximab, Rituxan), Other	Be consistent with current clinical landscape, improve transplant outcome
Essential Data		ves	ves	,	Rituxan), Other agent	.	apply)	agent	data
Pre- Transplant Essential Data		1		Was mechanical ventilation used for COVID-19 (SARS-CoV-	No,Yes	Change/Clarification of Information Requested	Was mechanical ventilation used- given for COVID-19 (SARS-CoV-2) infection?	No,Yes	Examples added or typographical errors corrected for clarification

	Information Collection Domain Additional Sub Domain	Response required if Additional Sub Domain applies	Collection may be requested	Element (if	Collection Data Element Response	Information Collection update:	Proposed Information Collection Data Element (if applicable)	Proposed Information Collection Data Element Response Option(s)	Rationale for Information Collection Update
			-		Breast cancer			Breast cancer	
					Central nervous			Central nervous system	
					system (CNS)			(CNS) malignancy (e.g.,	
					malignancy (e.g.,			glioblastoma, astrocytoma)	
					glioblastoma,			Gastrointestinal malignancy	
					astrocytoma)			(e.g., colon, rectum,	
					Gastrointestinal			stomach, pancreas,	
					malignancy (e.g.,			intestine, esophageal)	
					colon, rectum,			Genitourinary malignancy	
					stomach, pancreas,			(e.g., kidney, bladder, ovary,	
					intestine, esophageal)			testicle, genitalia, uterus,	
					Genitourinary			cervix, prostate)	
					malignancy (e.g.,			Leukemia Acute myeloid	
					kidney, bladder,			leukemia	
					ovary, testicle,			Chronic myeloid leukemia	
					genitalia, uterus,			Acute lymphoblastic	
					cervix, prostate)			leukemia	
					Leukemia			Chronic lymphoblastic	
					Lung cancer			leukemia	
					Lymphoma (includes			Lung cancer	
					Hodgkin & non-			Lymphoma (includes	
					Hodgkin lymphoma)			Hodgkin & non-Hodgkin	
					MDS / MPN			lymphoma)	
					Melanoma			MDS / MPN	
					Multiple myeloma /			Melanoma	
Pre-				' ''	plasma cell disorder				Be consistent with current clinical
Transplant	Comorbid			0 , ((PCD)	Change/Clarification of	Specify prior malignancy (check	cell disorder (PCD)	landscape, improve transplant outcome
Essential Data	Conditions	Yes	no	that apply)	Oropharyngeal cancer	Response Options	all that apply)	Oropharyngeal cancer (e.g.,	data
Pre-									
Transplant Transplant	Comorbid			Specify other skin		Deletion of Information	Specify other skin malignancy:		
Essential Data	Conditions	Yes	no	malignancy: (prior)	open text	Requested	(prior)	open text	Reduce redundancy in data capture
Pre-				Height at initiation of	inches			inches	
Transplant				pre-HCT preparative	cms	Change/Clarification of	Height at initiation of pre-HCT	cms	
Essential Data		no	no	regimen:		Response Options	preparative regimen:		Capture data accurately

	Information Collection Domain Additional Sub Domain	Response required if Additional Sub Domain applies	Collection may be requested	Element (if	Current Information Collection Data Element Response Option(s)	Information Collection update:	Proposed Information Collection Data Element (if applicable)	Response Option(s)	Rationale for Information Collection Update
					Dondonovskima Dvavilea			Bendamustine, Busulfan, Car	
					Bendamustine, Busulfan, Carboplatin, Carmust			boplatin, Carmustine, Clofara bine, Cyclophosphamide, Cyt	
					ine,Clofarabine,Cyclop			arabine, Etoposide, Fludarabi	
					hosphamide,Cytarabin			ne,Gemcitabine,Ibritumom	
					e,Etoposide,Fludarabi			ab	
					ne,Gemcitabine,Ibritu			tiuxetan,Ifosfamide,Lomusti	
					momab			ne,Melphalan,Methylpredni	
					tiuxetan, Ifosfamide, Lo			solone,Other,Pentostatin,Pr	
					mustine, Melphalan, M			opylene glycol-free	
					ethylprednisolone,Oth			melphalan,Rituximab,Thiot	
					er,Pentostatin,Propyle			epa,Tositumomab,Treosulfa	
					ne glycol-free			n, Azathioprine,	
Pre-HCT					melphalan,Rituximab,			Bortezomib, Cisplatin,	Be consistent with current clinical
Preparative					Thiotepa, Tositumoma	Change/Clarification of	5 (1 1 1 1)	Hydroxyurea, and	landscape, improve transplant outcome
Regimen Additional		no	no	Drug (drop down list)	b,Treosulfan	Response Options	Drug (drop down list)	Vincristine.	data
Drugs Given									Reduce burden: expanded response
In the Peri-						Change/Clarification of	ALG, ALS, ATG, ATS,		options to include responses previously
Transplant						Information Requested and	Alemtuzumab, Defibrotide, KGF,		reported manually or created a "check all
Period		no	no	ALG, ALS, ATG, ATS	no,yes	Response Option	Ursodiol	no, yes (check all that apply)	
Additional				,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	,	· · · · · · · · · · · · · · · · · · ·		me, y es (en est an en es app.y)	опистриту
Drugs Given									Reduce burden: expanded response
In the Peri-									options to include responses previously
Transplant				Alemtuzumab		Deletion of Information:			reported manually or created a "check all
Period		no	no	(Campath)	no,yes	Merged to Check all that Apply	Alemtuzumab (Campath)	no,yes	that apply"
Additional									
Drugs Given									Reduce burden: expanded response
In the Peri-						5 1 11 11 11			options to include responses previously
Transplant				Defile estide	N = V = =	Deletion of Information:	Defilement	No Vee	reported manually or created a "check all
Period Additional		no	no	Defibrotide	No,Yes	Merged to Check all that Apply	Denorotide	No,Yes	that apply"
Drugs Given									Reduce burden: expanded response
In the Peri-									options to include responses previously
Transplant						Deletion of Information:			reported manually or created a "check all
Period		no	no	KGF	No,Yes	Merged to Check all that Apply	KGF	No,Yes	that apply"

Domain Sub- Type	Information Collection Domain Additional Sub Domain	Response required if Additional Sub Domain applies	Collection may be requested	Element (if	Current Information Collection Data Element Response Option(s)	Information Collection update:	Proposed Information Collection Data Element (if applicable)	Proposed Information Collection Data Element Response Option(s)	Rationale for Information Collection Update
Additional Drugs Given In the Peri- Transplant						Deletion of Information:			Reduce burden: expanded response options to include responses previously reported manually or created a "check all
Period		no	no	Ursodiol	No,Yes	Merged to Check all that Apply	Ursodiol	No,Yes	that apply"
Covid-19 Impa	act	no	no			Addition of Information Requested	Was the HCT impacted for a reason related to the COVID-19 (SARS-CoV-2) pandemic?	no,yes	Covid-19 Impact
Covid-19 Impa	oct	no	no			Addition of Information Requested	Is the HCT date different than the originally intended HCT date?	no,yes	Covid-19 Impact
Covid-19 Impa	act	no	no			Addition of Information Requested	Original Date of HCT	YYYY/MM/DD	Covid-19 Impact
Covid-19 Impa	oct	no	no			Addition of Information Requested	Date estimated	checked	Covid-19 Impact
Covid-19 Impa	act	no	no			Addition of Information Requested	Is the donor different than the originally intended donor?	no,yes	Covid-19 Impact
								unrelated donor, syngeneic (monozygotic twin), HLA- idential sibling (may include non-monozygotic twin), HLA-matched other relative (does NOT include a haplo-	
						Addition of Information	Specify the originally intended	identical donor), HLA-	
Covid-19 Impa	ict	no	no			Requested	donor	mismatched relative	Covid-19 Impact
Covid 10 la	.ot					Addition of Information	Is the product type (bone marrow, PBSC, cord blood unit) different than the originally intended product type?	20 105	Could 10 Impact
Covid-19 Impa		no	no			Requested Addition of Information	intended product type? Specify the originally intended	no,yes bone marrow,Other product,PBSC, cord blood	Covid-19 Impact
Covid-19 Impa	ect	no	no			Requested	product type	unit	Covid-19 Impact

Information Collection Domain Sub Type	Information Collection Domain Additional Sub Domain	Response required if Additional Sub Domain applies	be requested	Element (if	Current Information Collection Data Element Response Option(s)	Information Collection update:	Proposed Information Collection Data Element (if applicable)	Proposed Information Collection Data Element Response Option(s)	Rationale for Information Collection Update
						Addition of Information			
Covid-19 Impa	ict	no	no			Requested	Specify other product type	open text	Covid-19 Impact
							Was the current product thawed		
						Addition of Information	from a cryopreserved state prior		
Covid-19 Impa	ect	no	no			Requested	to infusion?	no,yes	Covid-19 Impact
						Addition of Information	Did the proparative regimen		
Cavid 10 January							Did the preparative regimen		Cavid 10 Immark
Covid-19 Impa	ict	no	no			Requested	change from the original plan?	no, yes	Covid-19 Impact
						Addition of Information	Did the GVHD prophylaxis change		
Covid-19 Impa	ect	no	no			Requested	from the original plan?	no,yes	Covid-19 Impact

	Information Collection Domain Additional Sub Domain	Response required if Additional Sub Domain applies	Collection may be requested	Element (if	Current Information Collection Data Element Response Option(s)	Information Collection update:	Proposed Information Collection Data Element (if applicable)	Proposed Information Collection Data Element Response Option(s)	Rationale for Information Collection Update
					diseases,Acute			diseases,Acute	
					lymphoblastic			lymphoblastic leukemia	
					leukemia (ALL),Acute			(ALL),Acute myelogenous	
					myelogenous			myeloid leukemia (AML or	
					leukemia (AML or			ANLL),Chronic myelogenous	
					ANLL),Chronic			leukemia	
					myelogenous			(CML),Hemoglobinopathies,	
					leukemia			Histiocytic	
					(CML),Hemoglobinopa			disorders,Hodgkin	
					thies, Histiocytic			lymphoma,Inherited Bone	
					disorders,Hodgkin			Marrow Failure	
					lymphoma,Inherited			Syndromes(If the recipient	
					Bone Marrow Failure			developed MDS or AML,	
					Syndromes(If the			indicate MDS or AML as the	
					recipient developed			primary disease.)–	
					MDS or AML, indicate			,Disorders of the immune	
					MDS or AML as the			system,Inherited disorders	
					primary disease.)–			of metabolism,Inherited	
					Disorders of the			abnormalities of	
					immune			platelets, Myelodysplastic	
					system,Inherited			syndrome (MDS) (If	
					disorders of			recipient has transformed	
					metabolism,Inherited			to AML, indicate AML as the	
					abnormalities of			primary	
				What was the primary				disease.),Myeloproliferative	
				disease for which the			What was the primary disease for		
Disease				HCT / cellular therapy	· ·	Change/Clarification of		recipient has transformed	
Classification		no	no	was performed?	transformed to AML,	Response Options	was performed?	to AML, indicate AML as the	Capture data accurately
	Acuto			More sytegenetics			Wors sytagonatics tasted		
Disease	Acute			Were cytogenetics		Change/Clarification of	Were cytogenetics tested		
Disease Classification	Myelogenous Leukemia (AML)	wos	wos	tested (karyotyping or	no Unknown voc		(karyotyping or FISH)? (at	no Unknown yes	Poduco rodundancy is data contura
Classification	Leukeiiiid (Alvit)	yes	yes	FISH)? (at diagnosis) Were tests for	no,Unknown,yes	Information Requested	diagnosis or relapse)	no,Unknown,yes	Reduce redundancy in data capture
	Acuto			molecular markers			Were tests for molecular markers		
Disease	Acute Myelogenous			performed? (at		Change/Clarification of	performed? (at diagnosis or		
Disease		VOS	WOS		no Unknown voc	_		no Unknown yes	Poduco rodundancy in data conturo
Classification	Leukemia (AML)	yes	yes	diagnosis)	no,Unknown,yes	Information Requested	relapse)	no,Unknown,yes	Reduce redundancy in data capture

	Information								
Information	Collection	Response	Information	Current Information	Current Information				
	Domain	required if	•		Collection Data		Proposed Information	Proposed Information	
Domain Sub-	Additional Sub	Additional Sub	be requested	Element (if	Element Response	Information Collection	Collection Data Element (if	Collection Data Element	Rationale for Information Collection
Туре	Domain	Domain applies	multiple times	applicable)	Option(s)	update:	applicable)	Response Option(s)	Update
					Biallelic				
					(homozygous), Monoal				
	Acute				lelic			Biallelic (double	
Disease	Myelogenous			Specify CEBPA	(heterozygous),Unkno	Change/Clarification of		mutant), Monoallelic (single	
Classification	Leukemia (AML)	yes	yes	mutation	wn	Response Options	Specify CEBPA mutation	mutant),Unknown	Capture data accurately
				Were cytogenetics					
				tested (karyotyping or			Were cytogenetics tested		
	Acute			FISH)? (between			(karyotyping or FISH)? (between		
Disease	Myelogenous			diagnosis and last		Change/Clarification of	diagnosis or relapse and last		
Classification	Leukemia (AML)	yes	yes	evaluation)	no,Unknown,yes	Information Requested	evaluation)	no,Unknown,yes	Reduce redundancy in data capture
				Were tests for					
				molecular markers					
				performed? (e.g. PCR,			Were tests for molecular markers		
	Acute			NGS) (between			performed? (e.g. PCR, NGS)		
Disease	Myelogenous			diagnosis and last		Change/Clarification of	(between diagnosis or relapse		
Classification	Leukemia (AML)	yes	yes	evaluation)	no,Unknown,yes	Information Requested	and last evaluation)	no,Unknown,yes	Reduce redundancy in data capture
					Biallelic				
					(homozygous), Monoal				
	Acute				lelic			Biallelic (double	
	Myelogenous			Specify CEBPA	(heterozygous), Unkno	Change/Clarification of		mutant), Monoallelic (single	
Classification	Leukemia (AML)	yes	yes	mutation	wn	Response Options	Specify CEBPA mutation	mutant),Unknown	Capture data accurately
					Biallelic				
					(homozygous), Monoal				
	Acute				lelic			Biallelic (double	
Disease	Myelogenous			Specify CEBPA	(heterozygous), Unkno	Change/Clarification of		mutant), Monoallelic (single	
<u>Classification</u>	Leukemia (AML)	yes	yes	mutation	wn	Response Options	Specify CEBPA mutation	mutant),Unknown	Capture data accurately
	Acute			Was the recipient in	Not				
Disease	Myelogenous			remission by flow		Deletion of Information	Was the recipient in remission by	Not-	
Classification	Leukemia (AML)	yes	no	cytometry?	n,Yes	Requested	flow cytometry?	applicable,No,Unknown,Yes	Reduce redundancy in data capture
							Specify method(s) that was used		
	Acute						to assess measurable residual	FISH, Karyotyping, Flow	Be consistent with current clinical
Disease	Myelogenous					Addition of Information	disease status (check all that	Cytometry, PCR, NGS, Not	landscape, improve transplant outcome
<u>Classification</u>	Leukemia (AML)	yes	no			Requested	apply)	assessed	data
	Acute								Be consistent with current clinical
Disease	Myelogenous					Addition of Information	Was measurable residual disease		landscape, improve transplant outcome
Classification	Leukemia (AML)	yes	no			Requested	detected by FISH?	no,yes	data

Domain Sub-	Information Collection Domain Additional Sub Domain	Response required if Additional Sub Domain applies	be requested	Collection Data Element (if	Current Information Collection Data Element Response Option(s)	Information Collection update:	Proposed Information Collection Data Element (if applicable)	Proposed Information Collection Data Element Response Option(s)	Rationale for Information Collection Update
	Acute								Be consistent with current clinical
Disease	Myelogenous					Addition of Information	Was measurable residual disease		landscape, improve transplant outcome
Classification	Leukemia (AML)	yes	no			Requested	detected by karyotyping assay?	no,yes	data
	Acute						Which leukemia phenotype was	original leukemia	Be consistent with current clinical
	Myelogenous					Addition of Information	used for detection (check all the	immunophenotype,	landscape, improve transplant outcome
Classification	Leukemia (AML)	yes	no			Requested	apply)	aberrant phenotype	data
	Acute						What is the lower limit of		Be consistent with current clinical
Disease	Myelogenous					Addition of Information	detection (for the original		landscape, improve transplant outcome
Classification	Leukemia (AML)	yes	no			Requested	leukemia immunophenotype)	open text	data
	Acute						What is the lower limit of		Be consistent with current clinical
Disease	Myelogenous					Addition of Information	detection (for the aberrant		landscape, improve transplant outcome
Classification	Leukemia (AML)	yes	no			Requested	phenotype)	open text	data
	Acute								Be consistent with current clinical
Disease	Myelogenous					Addition of Information	Was measurable residual disease		landscape, improve transplant outcome
Classification	Leukemia (AML)	yes	no			Requested	detected by flow cytometry?	no,yes	data
	Acute								Be consistent with current clinical
Disease	Myelogenous					Addition of Information	Was measurable residual disease		landscape, improve transplant outcome
Classification	Leukemia (AML)	yes	no			Requested	detected by PCR?	no,yes	data
	Acute								Be consistent with current clinical
Disease	Myelogenous					Addition of Information	Was measurable residual disease		landscape, improve transplant outcome
Classification	Leukemia (AML)	yes	no			Requested	detected by NGS?	no,yes	data
	Acute			Were cytogenetics			Were cytogenetics tested		
Disease	Lymphoblastic			tested (karyotyping or		Change/Clarification of	(karyotyping or FISH)? (at		
Classification	Leukemia (ALL)	yes	yes	FISH)? (at diagnosis)	no,Unknown,yes	Information Requested	diagnosis or relapse)	no,Unknown,yes	Reduce redundancy in data capture
				Were tests for					
	Acute			molecular markers			Were tests for molecular markers		
Disease	Lymphoblastic			performed? (at		Change/Clarification of	performed? (at diagnosis or		
Classification	Leukemia (ALL)	yes	yes	diagnosis)	no,Unknown,yes	Information Requested	relapse)	no,Unknown,yes	Reduce redundancy in data capture
				Were cytogenetics					
				tested (karyotyping or			Were cytogenetics tested		
	Acute			FISH)? (between			(karyotyping or FISH)? (between		
Disease	Lymphoblastic			diagnosis and last		Change/Clarification of	diagnosis or at relapse and last		
Classification	Leukemia (ALL)	yes	yes	evaluation)	no,Unknown,yes	Information Requested	evaluation)	no,Unknown,yes	Reduce redundancy in data capture

	Information								
Information	Collection	Response	Information	Current Information	Current Information				
Collection	Domain	required if	Collection may	Collection Data	Collection Data		Proposed Information	Proposed Information	
Domain Sub-	Additional Sub	Additional Sub	be requested	Element (if	Element Response	Information Collection	Collection Data Element (if	Collection Data Element	Rationale for Information Collection
Туре	Domain	Domain applies	multiple times	applicable)	Option(s)	update:	applicable)	Response Option(s)	Update
				Were tests for					
				molecular markers					
				performed? (e.g. PCR,			Were tests for molecular markers		
	Acute			NGS) (between			performed? (e.g. PCR, NGS)		
Disease	Lymphoblastic			diagnosis and last		Change/Clarification of	(between diagnosis or relapse		
<u>Classification</u>	Leukemia (ALL)	yes	yes	evaluation)	no,Unknown,yes	Information Requested	and last evaluation)	no,Unknown,yes	Reduce redundancy in data capture
	Acute			Was the recipient in	Not				
Disease	Lymphoblastic			remission by flow	The state of the s	Deletion of Information	Was the recipient in remission by	Not	
<u>Classification</u>	Leukemia (ALL)	yes	no	cytometry?	n,Yes	Requested	flow cytometry?	applicable,No,Unknown,Yes	Reduce redundancy in data capture
							Specify method(s) that was used		
	Acute						to assess measurable residual	FISH, Karyotyping, Flow	Be consistent with current clinical
Disease	Lymphoblastic					Addition of Information	disease status (check all that	Cytometry, PCR, NGS, Not	landscape, improve transplant outcome
Classification	Leukemia (ALL)	yes	no			Requested	apply)	assessed	data
	Acute								Be consistent with current clinical
Disease	Lymphoblastic					Addition of Information	Was measurable residual disease		landscape, improve transplant outcome
Classification	Leukemia (ALL)	yes	no			Requested	detected by FISH?	no,yes	data
	Acute								Be consistent with current clinical
Disease	Lymphoblastic					Addition of Information	Was measurable residual disease		landscape, improve transplant outcome
Classification	Leukemia (ALL)	yes	no			Requested	detected by karyotyping assay?	no,yes	data
	Acute						Which leukemia phenotype was	original leukemia	Be consistent with current clinical
Disease	Lymphoblastic					Addition of Information	used for detection (check all the	immunophenotype,	landscape, improve transplant outcome
Classification	Leukemia (ALL)	yes	no			Requested	apply)	aberrant phenotype	data
	Acute						What is the lower limit of		Be consistent with current clinical
Disease	Lymphoblastic					Addition of Information	detection (for the original		landscape, improve transplant outcome
Classification	Leukemia (ALL)	yes	no			Requested	leukemia immunophenotype)	open text	data
5:	Acute					A 1 1991	What is the lower limit of		Be consistent with current clinical
Disease	Lymphoblastic					Addition of Information	detection (for the aberrant		landscape, improve transplant outcome
Classification	Leukemia (ALL)	yes	no			Requested	phenotype)	open text	data
5:	Acute					A 1 1991			Be consistent with current clinical
Disease	Lymphoblastic					Addition of Information	Was measurable residual disease		landscape, improve transplant outcome
Classification	Leukemia (ALL)	yes	no			Requested	detected by flow cytometry?	no,yes	data
S.	Acute								Be consistent with current clinical
Disease	Lymphoblastic					Addition of Information	Was measurable residual disease		landscape, improve transplant outcome
Classification	Leukemia (ALL)	yes	no			Requested	detected by PCR?	no,yes	data

Domain Sub-	Domain Additional Sub	Response required if Additional Sub Domain applies	Collection may be requested	Element (if	Collection Data	Information Collection update:	Proposed Information Collection Data Element (if applicable)	Proposed Information Collection Data Element Response Option(s)	Rationale for Information Collection Update
	Acute								Be consistent with current clinical
Disease	Lymphoblastic					Addition of Information	Was measurable residual disease		landscape, improve transplant outcome
Classification	Leukemia (ALL)	yes	no			Requested	detected by NGS?	no,yes	data
				Specify the cell line					
	Myelodysplastic			examined to		Change/Clarification of	Specify the cell lines examined to		Examples added or typographical errors
Classification	Syndrome (MDS)	yes	no	determine HI status	HI-E,HI-N,HI-P	Information Requested	determine HI status	HI-E,HI-N,HI-P	corrected for clarification
								Lymphoma	
					Hodgkin lymphoma,			Lymphocyte depleted (154)	
					not otherwise			Lymphocyte-rich (151)	
					specified (150)			Mixed cellularity (153)	
					Lymphocyte depleted			Nodular sclerosis (152)	
					(154)			Other Classical Hodgkin	
					Lymphocyte-rich (151)			Lymphoma	
					Mixed cellularity (153)			Hodgkin lymphoma, not	
					Nodular lymphocyte			otherwise specified (150)	
					predominant Hodgkin			Nodular lymphocyte	
					lymphoma (155)			predominant Hodgkin	
					Nodular sclerosis			lymphoma	
					(152)			Non-Hodgkin Lymphoma	
					Non-Hodgkin			B-cell Neoplasms	
					Lymphoma			ALK+ large B-cell lymphoma	
					B-cell Neoplasms			(1833)	
					ALK+ large B-cell			B-cell lymphoma,	
					lymphoma (1833)			unclassifiable, with features	
					B-cell lymphoma,			intermediate between	
					unclassifiable, with			DLBCL and classical Hodgkin	
					features intermediate			lymphoma (149)	
					between DLBCL and			Burkitt lymphoma (111)	
					classical Hodgkin			Burkitt-like lymphoma with	
					lymphoma (149)			11q aberration (1834)	
					Burkitt lymphoma			Diffuse, large B-cell	
	Hodgkin and Non-				(111)				Be consistent with current clinical
Disease	Hodgkin			Specify the lymphoma		Change/Clarification of		type (non-GCB) (1821)	landscape, improve transplant outcome
Classification	•	yes	no			Response Options	Specify the lymphoma histology	Diffuse, large B-cell	data

Domain Sub-	Domain Additional Sub	•	Collection may be requested	Element (if applicable)	Current Information Collection Data Element Response Option(s)	Information Collection update:	Proposed Information Collection Data Element (if applicable)	Proposed Information Collection Data Element Response Option(s)	Rationale for Information Collection Update
				Is the lymphoma					
				histology reported at				/ 61	
S:	Hodgkin and Non-			transplant a			Is the lymphoma histology	no,yes (Also complete	
	Hodgkin			transformation from		Change/Clarification of	reported at transplant a	Chronic Lymphocytic	Capture additional relevent disease
Classification	Lympnoma	yes	no	CLL?	no,yes	Response Options	transformation from CLL?	Leukemia (CLL))	information
	Multiple Myeloma								
Disease	/ Plasma Cell			Plasma cells in blood		Change/Clarification of	Plasma cells in peripheral blood		
	Disorder (PCD)	yes	no	by flow cytometry	Known, Unknown	Information Requested	by flow cytometry	Known,Unknown	Capture data accurately
Classification	Disorder (Feb)	yes	110	by now cytometry	Kilowii, Olikilowii	mormation requested	by now cytometry	Kilowii, olikilowii	cupture data decaratery
	Multiple Myeloma			Plasma cells in blood					
Disease	/ Plasma Cell			by morphologic		Change/Clarification of	Plasma cells in peripheral blood		
Classification		yes	no	assessment	Known,Unknown	Information Requested	by morphologic assessment	Known,Unknown	Capture data accurately
					Dyskeratosis congenita,Fanconi anemia,Severe congenital			Dyskeratosis congenita,Fanconi anemia,Severe congenital neutropenia,Diamond-	
					neutropenia, Diamond-			Blackfan	
	Inherited Bone			bone marrow failure	Blackfan		Specify the inherited bone	anemia,Shwachman-	Be consistent with current clinical
Disease	Marrow Failure			syndrome	anemia,Shwachman-	Change/Clarification of	marrow failure syndrome	Diamond, Other inherited	landscape, improve transplant outcome
Classification	Syndromes	yes	no		Diamond	Response Options	classification	bone failure syndromes	data
				Did the recipient					
				receive gene therapy					
	Inherited Bone			to treat the inherited			Did the recipient receive gene-		
Disease	Marrow Failure			bone marrow failure		Deletion of Information	therapy to treat the inherited		
Classification	Syndromes	yes	no	syndrome?	No,Yes	Requested	bone marrow failure syndrome?	No,Yes	Reduce redundancy in data capture
				Did the recipient					
				receive gene therapy		_ , , , _ , , , , ,	Did the recipient receive gene		
	Hemoglobinopathi			to treat the		Deletion of Information	therapy to treat the		
Classification	es	yes	no	hemoglobinopathy?	No,Yes	Requested	hemoglobinopathy?	No,Yes	Reduce redundancy in data capture

Information Collection Domain Sub-	Information Collection Domain Additional Sub Domain	Response required if Additional Sub Domain applies	Collection may be requested	Element (if	Current Information Collection Data Element Response Option(s)	Information Collection update:	Proposed Information Collection Data Element (if applicable)	Proposed Information Collection Data Element Response Option(s)	Rationale for Information Collection Update
71					y (ALD) (543), Aspartyl		The second	leukoencephalopathy with	
					glucosaminidase			spheroids,	
					(561),ß-glucuronidase			Adrenoleukodystrophy	
					deficiency (VII)			(ALD) (543),Aspartyl	
					(537),Fucosidosis			glucosaminidase (561),ß-	
					(562),Gaucher disease			glucuronidase deficiency	
					(541),Glucose storage			(VII) (537),Fucosidosis	
					disease (548), Hunter			(562),Gaucher disease	
					syndrome (II)			(541),Glucose storage	
					(533),Hurler			disease (548), Hunter	
					syndrome (IH) (531),I-			syndrome (II) (533),Hurler	
					cell disease			syndrome (IH) (531),I-cell	
					(546),Krabbe disease			disease (546),Krabbe	
					(globoid			disease (globoid	
					leukodystrophy)			leukodystrophy) (544),Lesch	
					(544),Lesch-Nyhan			Nyhan (HGPRT deficiency)	
					(HGPRT deficiency)			(522), Mannosidosis	
					(522), Mannosidosis			(563),Maroteaux-Lamy (VI)	
					(563),Maroteaux-			(536),Metachromatic	
					Lamy (VI)			leukodystrophy (MLD)	
					(536), Metachromatic			(542), Mucolipidoses, not	
					leukodystrophy (MLD)			otherwise specified	
					(542), Mucolipidoses,			(540),Morquio (IV)	
					not otherwise			(535),Mucopolysaccharidosi	
				Specify inherited	specified			s (V)	
	Inherited			disorders of	(540),Morquio (IV)				Be consistent with current clinical
Disease	Disorders of			metabolism		Change/Clarification of	Specify inherited disorders of		landscape, improve transplant outcome
Classification	Metabolism	yes	no	classification	ridosis (V)	Response Options	metabolism classification	(530),Niemann-Pick disease	data
					Room temperature,				
Hematopoieti					Cooled (refrigerator			Room temperature, Cooled	
c Cellular					temperature, not			(refrigerated gel pack,	
Transplant				Consideration altitude	frozen), Frozen			refrigerator temperature,	
(HCT)				Specify the shipping	(cyropreserved),	Change /Clavification of	Considerable ability in a positive second	not frozen), Frozen	Francisco added ov transcondisco
Infusion					Other shipping	Change/Clarification of		1	Examples added or typographical errors
Product		no	no	product(s)	enfivronment	Response Options	of the product(s)	shipping enfivronment	corrected for clarification

Information Collection Domain Sub-		Response required if Additional Sub Domain applies	Collection may be requested	Element (if	Current Information Collection Data Element Response Option(s)	Information Collection update:	Proposed Information Collection Data Element (if applicable)	Proposed Information Collection Data Element Response Option(s)	Rationale for Information Collection Update
Hematopoieti									
c Cellular Transplant									
(HCT)					Flow cytometry			Flow cytometry based	
Infusion				Method of testing TNC		Change/Clarification of		(7AAD, AOPI, AOEB),Other	Examples added or typographical errors
Product		no	yes	viability	method,Trypan blue	Response Options	Method of testing TNC viability	method,Trypan blue	corrected for clarification
Hematopoieti									
c Cellular									
Transplant									
(HCT)					Flow cytometry			Flow cytometry based	
Infusion				_	based,Other	Change/Clarification of	Method of testing CD34+ cell	(7AAD, AOPI, AOEB), Other	Examples added or typographical errors
Product Hematopoieti		no	yes	CD34+ cell viability	method,Trypan blue	Response Options	viability	method,Trypan blue	corrected for clarification
c Cellular									
Transplant									
(HCT)					Flow cytometry			Flow cytometry based	
Infusion					based,Other	Change/Clarification of	Method of testing CD3+ cell	(7AAD, AOPI, AOEB), Other	Examples added or typographical errors
Product		no	yes	CD3+ cell viability	method,Trypan blue	Response Options	viability	method,Trypan blue	corrected for clarification
Hematopoieti									
c Cellular									
Transplant									
(HCT)					Flow cytometry	Change /Clarification of	Mark and of tracking CD2 (CD4), and	Flow cytometry based	English and the description of the control of the c
Infusion Product		200	wos		based,Other method,Trypan blue	Change/Clarification of Response Options	Method of testing CD3+CD4+ cell viability	method,Trypan blue	Examples added or typographical errors corrected for clarification
Hematopoieti		no	yes	viability	method, rrypan blue	Response Options	Viability	method, if ypan blue	corrected for clarification
c Cellular									
Transplant									
(HCT)				Method of testing	Flow cytometry			Flow cytometry based	
Infusion					based,Other	Change/Clarification of	Method of testing CD3+CD8+ cell		Examples added or typographical errors
Product		no	yes	viability	method,Trypan blue	Response Options	viability	method,Trypan blue	corrected for clarification
Hematopoieti c Cellular Transplant									Reduce burden: expanded response options to include responses previously
(HCT) Product	Cord Blood						Indicate which Assessments were	Total CFU-GM, Total CFU-	reported manually or created a "check all
Infusion	Product Infusion	yes	yes	Total CFU-GM	Done,Not done	Merged to Check all that Apply	Carried out (Check all that apply)	*	that apply"

Domain Sub-	Domain Additional Sub	Response required if Additional Sub Domain applies	be requested '	Element (if	Current Information Collection Data Element Response Option(s)	Information Collection	Proposed Information Collection Data Element (if applicable)	Proposed Information Collection Data Element Response Option(s)	Rationale for Information Collection Update
Hematopoieti c Cellular Transplant (HCT) Product Infusion	Cord Blood	yes	yes	Total CFU-GEMM	Done,Not done	Merged to Check all that Apply	Total CFU-GEMM	Done,Not done	Reduce burden: expanded response options to include responses previously reported manually or created a "check all that apply"
Hematopoieti c Cellular Transplant (HCT) Product Infusion		yes	yes	Total BFU-E	Done,Not done	Merged to Check all that Apply	Total BFU-E	Done,Not done	Reduce burden: expanded response options to include responses previously reported manually or created a "check all that apply"

	Information								
Information	Collection	Response		Current Information	Current Information				
Collection	Domain	required if	Collection may	Collection Data	Collection Data		<u> </u>	Proposed Information	
Domain Sub-	Additional Sub	Additional Sub	be requested	Element (if	Element Response	Information Collection	Collection Data Element (if	Collection Data Element	Rationale for Information Collection
Туре	Domain	Domain applies	multiple times	applicable)	Option(s)	update:	applicable)	Response Option(s)	Update
					121 inetobacter (all			inetobacter (all species),	
					species), 125			125 Bordetella pertussis	
					Bordetella pertussis			(whooping cough), 128	
					(whooping cough),			Campylobacter (all species),	
					128 Campylobacter			129 Capnocytophaga (all	
					(all species), 129			species), 171 Chlamydia	
					Capnocytophaga (all			(pneumoniae), 130	
					species), 171			Citrobacter (freundii, other	
					Chlamydia			species), 131 Clostridium	
					(pneumoniae), 130			(all species except difficile),	
					Citrobacter (freundii,			132 Clostridium difficile,	
					other species), 131			173 Corynebacterium	
					Clostridium (all			jeikeium, 134 Enterobacter	
					species except			(all species), 135	
					difficile), 132			Enterococcus (all species),	
					Clostridium difficile,			177 Enterococcus,	
					173 Corynebacterium			vancomycin resistant (VRE),	
					jeikeium, 134			136 Escherichia (also E.	
					Enterobacter (all			coli), 139 Fusobacterium (all	
					species), 135			species), 187 Haemophilus	
					Enterococcus (all			influenzae, 188	
					species), 177			Haemophilus non-	
					Enterococcus,			influenzae, 146 Klebsiella	
Hematopoieti					vancomycin resistant			(all species), 147	
<mark>c Cellular</mark>					(VRE), 136 Escherichia			Lactobacillus (bulgaricus,	
Transplant					(also E. coli), 139			acidophilus, other species),	
(HCT) Product				Specify Organism	Fusobacterium (all	Change/Clarification of		189 Legionella	Examples added or typographical errors
Infusion	Product Analysis	yes	yes	Code(s):	species), 187	Response Options	Specify Organism Code(s):	pneumophila, 190	corrected for clarification

	Information								
Information	Collection	Response		Current Information	Current Information				
Collection	Domain	required if	Collection may	Collection Data	Collection Data		<u> </u>	Proposed Information	
Domain Sub-	Additional Sub	Additional Sub	be requested	Element (if	Element Response	Information Collection	Collection Data Element (if	Collection Data Element	Rationale for Information Collection
Туре	Domain	Domain applies	multiple times	applicable)	Option(s)	update:	applicable)	Response Option(s)	Update
					121 inetobacter (all			inetobacter (all species),	
					species), 125			125 Bordetella pertussis	
					Bordetella pertussis			(whooping cough), 128	
					(whooping cough),			Campylobacter (all species),	
					128 Campylobacter			129 Capnocytophaga (all	
					(all species), 129			species), 171 Chlamydia	
					Capnocytophaga (all			(pneumoniae), 130	
					species), 171			Citrobacter (freundii, other	
					Chlamydia			species), 131 Clostridium	
					(pneumoniae), 130			(all species except difficile),	
					Citrobacter (freundii,			132 Clostridium difficile,	
					other species), 131			173 Corynebacterium	
					Clostridium (all			jeikeium, 134 Enterobacter	
					species except			(all species), 135	
					difficile), 132			Enterococcus (all species),	
					Clostridium difficile,			177 Enterococcus,	
					173 Corynebacterium			vancomycin resistant (VRE),	
					jeikeium, 134			136 Escherichia (also E.	
					Enterobacter (all			coli), 139 Fusobacterium (all	
					species), 135			species), 187 Haemophilus	
					Enterococcus (all			influenzae, 188	
					species), 177			Haemophilus non-	
					Enterococcus,			influenzae, 146 Klebsiella	
Hematopoieti					vancomycin resistant			(all species), 147	
<mark>c Cellular</mark>					(VRE), 136 Escherichia			Lactobacillus (bulgaricus,	
Transplant					(also E. coli), 139			acidophilus, other species),	
(HCT) Product				Specify Organism	Fusobacterium (all	Change/Clarification of		189 Legionella	Examples added or typographical errors
Infusion	Product Analysis	yes	yes	Code(s):	species), 187	Response Options	Specify Organism Code(s):	pneumophila, 190	corrected for clarification

	Information								
Information	Collection	Response		Current Information	Current Information				
Collection	Domain	required if	Collection may	Collection Data	Collection Data		<u> </u>	Proposed Information	
Domain Sub-	Additional Sub	Additional Sub	be requested	Element (if	Element Response	Information Collection	Collection Data Element (if	Collection Data Element	Rationale for Information Collection
Туре	Domain	Domain applies	multiple times	applicable)	Option(s)	update:	applicable)	Response Option(s)	Update
					121 inetobacter (all			inetobacter (all species),	
					species), 125			125 Bordetella pertussis	
					Bordetella pertussis			(whooping cough), 128	
					(whooping cough),			Campylobacter (all species),	
					128 Campylobacter			129 Capnocytophaga (all	
					(all species), 129			species), 171 Chlamydia	
					Capnocytophaga (all			(pneumoniae), 130	
					species), 171			Citrobacter (freundii, other	
					Chlamydia			species), 131 Clostridium	
					(pneumoniae), 130			(all species except difficile),	
					Citrobacter (freundii,			132 Clostridium difficile,	
					other species), 131			173 Corynebacterium	
					Clostridium (all			jeikeium, 134 Enterobacter	
					species except			(all species), 135	
					difficile), 132			Enterococcus (all species),	
					Clostridium difficile,			177 Enterococcus,	
					173 Corynebacterium			vancomycin resistant (VRE),	
					jeikeium, 134			136 Escherichia (also E.	
					Enterobacter (all			coli), 139 Fusobacterium (all	
					species), 135			species), 187 Haemophilus	
					Enterococcus (all			influenzae, 188	
					species), 177			Haemophilus non-	
					Enterococcus,			influenzae, 146 Klebsiella	
Hematopoieti					vancomycin resistant			(all species), 147	
<mark>c Cellular</mark>					(VRE), 136 Escherichia			Lactobacillus (bulgaricus,	
Transplant					(also E. coli), 139			acidophilus, other species),	
(HCT) Product				Specify Organism	Fusobacterium (all	Change/Clarification of		189 Legionella	Examples added or typographical errors
Infusion	Product Analysis	yes	yes	Code(s):	species), 187	Response Options	Specify Organism Code(s):	pneumophila, 190	corrected for clarification

	Information Collection Domain Additional Sub Domain	Response required if Additional Sub Domain applies	Collection may be requested	Element (if	Collection Data Element Response	Information Collection update:	Proposed Information Collection Data Element (if applicable)	Proposed Information Collection Data Element Response Option(s)	Rationale for Information Collection Update
71		2 2 1 1 1 1 1 2 1		- Prince of	121 inetobacter (all		The second	inetobacter (all species),	
					species), 125			125 Bordetella pertussis	
					Bordetella pertussis			(whooping cough), 128	
					(whooping cough),			Campylobacter (all species),	
					128 Campylobacter			129 Capnocytophaga (all	
					(all species), 129			species), 171 Chlamydia	
					Capnocytophaga (all			(pneumoniae), 130	
					species), 171			Citrobacter (freundii, other	
					Chlamydia			species), 131 Clostridium	
					(pneumoniae), 130			(all species except difficile),	
					Citrobacter (freundii,			132 Clostridium difficile,	
					other species), 131			173 Corynebacterium	
					Clostridium (all			jeikeium, 134 Enterobacter	
					species except			(all species), 135	
					difficile), 132			Enterococcus (all species),	
					Clostridium difficile,			177 Enterococcus,	
					173 Corynebacterium			vancomycin resistant (VRE),	
					jeikeium, 134			136 Escherichia (also E.	
					Enterobacter (all			coli), 139 Fusobacterium (all	
					species), 135			species), 187 Haemophilus	
					Enterococcus (all			influenzae, 188	
					species), 177			Haemophilus non-	
					Enterococcus,			influenzae, 146 Klebsiella	
Hematopoieti					vancomycin resistant			(all species), 147	
<mark>c Cellular</mark>					(VRE), 136 Escherichia			Lactobacillus (bulgaricus,	
Transplant Transplant					(also E. coli), 139			acidophilus, other species),	
(HCT) Product				Specify Organism	Fusobacterium (all	Change/Clarification of		189 Legionella	Examples added or typographical errors
Infusion	Product Analysis	yes	yes	Code(s):	species), 187	Response Options	Specify Organism Code(s):	pneumophila, 190	corrected for clarification
5				6 (6 1)					
Post-				Specify the recipient's			Consideration of the constant	Alive Deed (C	
Transplant Formula Date				survival status at the	Alina Dand	Change/Clarification of	Specify the recipient's survival	Alive, Dead (Complete	Capture additional relevent disease
Essential Data		no	yes	date of last contact	Alive,Dead	Response Options	status at the date of last contact	recipient death data)	information
Post									
Post-	Subsequent					Addition of Information	Was this infusion a donor		Capture additional relevent disease
Transplant Essential Data		vos	wos					no vos	
essentiai Data	rranspiant	yes	yes			Requested	lymphocyte infusion (DLI)?	no,yes	information

Information Collection Domain Sub-	Information Collection Domain Additional Sub Domain	1 -	Collection may be requested	Element (if	Current Information Collection Data Element Response Option(s)	Information Collection update:	Proposed Information Collection Data Element (if applicable)	Proposed Information Collection Data Element Response Option(s)	Rationale for Information Collection Update
Post-									
Transplant Essential Data	Subsequent Transplant	yes	yes			Addition of Information Requested	Number of DLIs in this reporting period		Capture additional relevent disease information
Post- Transplant	Subsequent	yes	yes			Addition of Information	Are any of the products, associated with this course of cellular therapy, genetically		Capture additional relevent disease
Essential Data		yes	yes			Requested	modified?	no, yes	information
Post- Transplant Essential Data	Graft vs. Host Disease	yes	yes	Date maximum overall grade of acute GVHD:	YYYY/MM/DD	Change/Clarification of Information Requested	First date maximum overall grade of acute GVHD:	YYYY/MM/DD	Capture data accurately
Post- Transplant	Graft vs. Host					Deletion of Information:			Reduce burden: expanded response options to include responses previously reported manually or created a "check all
Essential Data Post-	Discuse.	yes	yes	Date estimated	Defibrotide,N-acetylcysteine,Other therapy,Tissue	Merged to Check all that Apply	Juce estimated	Defibrotide,N- acetylcysteine,Other therapy,Tissue plasminogen activator (TPA),Ursodiol,	that apply" Be consistent with current clinical
Transplant				Specify therapy (check	plasminogen activator	Change/Clarification of	Specify therapy (check all that	Enoxaparin (Lovenox),	landscape, improve transplant outcome
Essential Data		no	yes	all that apply)	(TPA),Ursodiol	Response Options	apply)	Heparin	data
				Did a new malignancy, myelodysplastic, myeloproliferative, or					
				lymphoproliferative disease / disorder occur that is different			Did a new malignancy, myelodysplastic, myeloproliferative, or		
Post-				from the disease / disorder for which the HCT or cellular			lymphoproliferative disease / disorder occur that is different from the disease / disorder for	No,Yes (Also complete	
Transplant Essential Data		no	yes	therapy was performed?	No,Yes	Change/Clarification of Response Options	which the HCT or cellular therapy was performed?	Subsequent Neoplasms) , previosly reported	Capture additional relevent disease information

Information Collection Domain Sub-	Information Collection Domain Additional Sub Domain	required if	Collection may be requested	Current Information Collection Data Element (if applicable)	Current Information Collection Data Element Response Option(s)	Information Collection update:	Proposed Information Collection Data Element (if applicable)	Proposed Information Collection Data Element Response Option(s)	Rationale for Information Collection Update
Post-									
	Chimerism Study					Change/Clarification of			
Essential Data	Performed	yes	yes	Date of birth:	YYYY/MM/DD	Information Requested	Donor Date of birth:	YYYY/MM/DD	Capture data accurately
Post-									
Transplant	Chimerism Study					Change/Clarification of			
Essential Data	Performed	yes	yes	Sex	female,male	Information Requested	Donor Sex	female,male	Capture data accurately
Post- Transplant Essential Data	Chimerism Study Performed	yes	yes	Method	Fluorescent in situ hybridization (FISH) for XX/XY,Karyotyping for XX/XY,Other,Restrictio n fragment-length polymorphisms (RFLP),VNTR or STR, micro or mini satellite	Change/Clarification of	Method	PCR(includes quantitative, real time, and fluorescent multiplex), Fluorescent in situ hybridization (FISH) for XX/XY,Karyotyping for XX/XY,Other,Restriction fragment-length polymorphisms (RFLP),VNTR or STR, micro or mini satellite	Examples added or typographical errors corrected for clarification
Post-									
	Chimerism Study			Were donor cells		Deletion of Information			
Essential Data	Performed	yes	yes	detected?	No,Yes	Requested	Were donor cells detected?	No,Yes	Reduce redundancy in data capture

Domain Sub-	Information Collection Domain Additional Sub Domain	•	Collection may be requested	Element (if	Current Information Collection Data Element Response Option(s)	Information Collection update:	Proposed Information Collection Data Element (if applicable)	Proposed Information Collection Data Element Response Option(s)	Rationale for Information Collection Update
					Alemtuzumab, Azacyti				
					dine,Blinatumomab,B				
					ortezomib,Bosutinib,C			Alemtuzumab, Azacytidine, B	
					arfilzomib,Chemother			linatumomab,Bortezomib,B	
					apy,Dasatinib,Decitabi			osutinib,Carfilzomib, Chemo	
					ne, Gemtuzumab, Gilte			therapy, Dasatinib, Decitabin	
					ritinib,Ibrutinib,Imatin			e,Gemtuzumab,Gilteritinib,I	
					ib			brutinib,Imatinib	
					mesylate,lxazomib,Le			mesylate,lxazomib,Lenalido	
					nalidomide,Lestaurtini			mide,Lestaurtinib,Midostau	
					b, Midostaurin, Nilotini			rin, Nilotinib, Nivolumab, Oth	
					b,Nivolumab,Other			er systemic	
					systemic			therapy,Pembrolizumab,Po	
					therapy,Pembrolizum			malidomide,Quizartinib,Ritu	
					ab,Pomalidomide,Qui			ximab,Sorafenib,Sunitinib,T	
					zartinib,Rituximab,Sor			halidomide, Brentuximab	Be consistent with current clinical
Post-HCT					afenib,Sunitinib,Thalid	Change/Clarification of	Specify systemic therapy (check	vendotin, Daratumumab	landscape, improve transplant outcome
Therapy		no	yes	apply)	omide	Response Options	all that apply)	(Darzalex)	data
							Did a fecal microbiota transplant		Be consistent with current clinical
Post-HCT						Addition of Information	(FMT) occur since the date of last		landscape, improve transplant outcome
Therapy		no	yes			Requested	report?	No, Yes	data
									Be consistent with current clinical
Post-HCT						Addition of Information			landscape, improve transplant outcome
Therapy		no	yes			Requested	Date of FMT	DD/MM/YY	data
								Graft versus host disease	Be consistent with current clinical
Post-HCT						Addition of Information			landscape, improve transplant outcome
Therapy		no	yes			Requested	Specify the indication for the FMT	Other	data
									Be consistent with current clinical
Post-HCT						Addition of Information			landscape, improve transplant outcome
Therapy		no	yes			Requested	Specify other indication:	open text	data

	Information								
	Collection	Response	Information		Current Information				
	Domain	required if	· -	Collection Data	Collection Data		Proposed Information	Proposed Information	
	Additional Sub	Additional Sub	be requested	Element (if	Element Response	Information Collection	Collection Data Element (if	Collection Data Element	Rationale for Information Collection
Туре	Domain	Domain applies	multiple times	applicable)	Option(s)	update:	applicable)	Response Option(s)	Update
					Alemtuzumab, Azacyti				
					dine,Blinatumomab,B				
					ortezomib,Bosutinib,C				
					arfilzomib,Chemother			Alemtuzumab, Azacytidine, B	
					apy,Dasatinib,Decitabi			linatumomab,Bortezomib,B	
					ne,Gemtuzumab,Gilte			osutinib,Carfilzomib,Chemo	
					ritinib,Ibrutinib,Imatin			therapy, Dasatinib, Decitabin	
					ib			e,Gemtuzumab,Gilteritinib,I	
					mesylate,lxazomib,Le			brutinib,Imatinib	
					nalidomide,Lestaurtini			mesylate,lxazomib,Lenalido	
					b,Midostaurin,Nilotini			mide,Lestaurtinib,Midostau	
					b,Nivolumab,Other			rin,Nilotinib,Nivolumab,Oth	
					systemic			er systemic	
					therapy,Pembrolizum			therapy,Pembrolizumab,Po	
					ab,Pomalidomide,Qui			malidomide,Quizartinib,Ritu	
Relapse or				Specify systemic	zartinib,Rituximab,Sor	61 (61) 5			Be consistent with current clinical
Progression				therapy (check all that		Change/Clarification of	Specify systemic therapy (check	halidomide, Daratumumb	landscape, improve transplant outcome
Post-HCT		no	yes	apply)	omide	Response Options	all that apply)	(Darzalex), Venetoclax	data
Current				Data of march march		Deletion of Information	Date of most recent disease		
Disease				Date of most recent	Ka ayya Halya ayya			Known.Unknown	Doduce reducedency in data continu
Status		no	yes	disease assessment	Known, Unknown	Requested	Date of most recent disease	KNOWN,UNKNOWN	Reduce redundancy in data capture
Current							assessment		
Current				Data of most recent		Change/Clarification of	Date of -assesment of current		
Disease Status		no	voc.	Date of most recent disease assessment:	YYYY/MM/DD	Information Requested	disease status	YYYY/MM/DD	Reduce redundancy in data capture
Status		no	yes	uisease assessifient.	T T T T IVIIVIIVI	Information Requested	disease status		neduce reduitabley in data capture
Recipient						Addition of Information			
Death Data	Recipient Death	yes	no			Requested	Date of death:	YYYY/MM/DD	Reduce redundancy in data capture
Death Data	Recipient Death	yes	110			nequested	Date of death.		neduce reduitedney in data capture
Recipient						Addition of Information			
Death Data	Recipient Death	yes	no			Requested	Date estimated	checked	Reduce redundancy in data capture
Death Data	Recipient Death	yes	ino			nequested	Date estimated	CHECKEU	neduce reduitedney in data capture
Recipient						Addition of Information	Was cause of death confirmed by	Autonsy	
Death Data	Recipient Death	ves	no			Requested	autopsy?	pending,No,Unknown,Yes	Reduce redundancy in data capture
Death Data	recipient beauti	yes	110			nequested	uatopsy:	penang, wo, onknown, res	mediace redundancy in data capture

Domain Sub-	Domain Additional Sub	· ·	Collection may be requested	Element (if	Current Information Collection Data Element Response Option(s)	Information Collection	Proposed Information Collection Data Element (if applicable)	Proposed Information Collection Data Element Response Option(s)	Rationale for Information Collection Update
Recipient						Addition of Information	Was documentation submitted to		
	Recipient Death	yes	no			Requested	the CIBMTR?	No,Yes	Reduce redundancy in data capture
					death,Acute GVHD,Adult respiratory distress syndrome (ARDS) (other than IPS),Bacterial infection,Cardiac failure,Chronic GVHD,Central nervous system (CNS) failure,COVID-19 (SARS-COV- 2),Cytokine release syndrome,Diffuse alveolar damage (without hemorrhage), Disseminated intravascular coagulation (DIC),Fungal infection, Gastrointestinal (GI) failure (not liver),Graft rejection or failure, Thrombotic			GVHD,Adult respiratory distress syndrome (ARDS) (other than IPS),Bacterial infection,Cardiac failure,Chronic GVHD,Central nervous system (CNS) failure,COVID-19 (SARS-CoV-2),Cytokine release syndrome,Diffuse alveolar damage (without hemorrhage),Diffuse alveolar hemorrhage (DAH),Disseminated intravascular coagulation (DIC),Fungal infection,Gastrointestinal hemorrhage,Gastrointestinal (GI) failure (not liver),Graft rejection or failure,Hemorrhagic cystitis,Thrombotic microangiopathy (TMA) (Thrombotic thrombocytopenic purpura (TTP)/Hemolytic Uremic	
Recipient				Primary cause of	microangiopathy (TMA) (Thrombotic	Change/Clarification of		pneumonia syndrome	Be consistent with current clinical landscape, improve transplant outcome
7	Recipient Death	yes	no	death	thrombocytopenic	Response Options	Primary cause of death	(IPS),Intracranial	data

Domain Sub-	Information Collection Domain Additional Sub Domain	I -	Collection may be requested	Element (if	Collection Data Element Response	Information Collection	Proposed Information Collection Data Element (if applicable)	Proposed Information Collection Data Element Response Option(s)	Rationale for Information Collection Update
					death,Acute			GVHD,Adult respiratory	
					GVHD,Adult			distress syndrome (ARDS)	
					respiratory distress			(other than IPS),Bacterial	
					syndrome (ARDS)			infection,Cardiac	
					(other than			failure,Chronic	
					IPS),Bacterial			GVHD,Central nervous	
					infection,Cardiac			system (CNS) failure,COVID-	
					failure,Chronic			19 (SARS-CoV-2), Cytokine	
					GVHD,Central nervous			release syndrome,Diffuse	
					system (CNS)			alveolar damage (without	
					failure,COVID-19			hemorrhage),Diffuse	
					(SARS-CoV-			alveolar hemorrhage	
					2),Cytokine release			(DAH), Disseminated	
					syndrome,Diffuse			intravascular coagulation	
					alveolar damage			(DIC),Fungal	
					(without			infection, Gastrointestinal	
					hemorrhage),			hemorrhage, Gastrointestin	
					Disseminated			al (GI) failure (not	
					intravascular			liver),Graft rejection or	
					coagulation			failure,Hemorrhagic	
					(DIC),Fungal infection,			cystitis,Thrombotic	
					Gastrointestinal (GI)			microangiopathy (TMA)	
					failure (not liver),Graft			(Thrombotic	
					rejection or failure,			thrombocytopenic purpura	
					Thrombotic			(TTP)/Hemolytic Uremic	
					microangiopathy				Be consistent with current clinical
Recipient				•	(TMA) (Thrombotic	Change/Clarification of		pneumonia syndrome	landscape, improve transplant outcome
Death Data	Recipient Death	yes	no	death	thrombocytopenic	Response Options	Contributing cause of death	(IPS),Intracranial	data

Information Collection	Domain	Response required if Additional Sub	Collection may	Current Information Collection Data Element (if	Current Information Collection Data Element Response	Information Collection	Proposed Information Collection Data Element (if	Proposed Information Collection Data Element	Rationale for Information Collection
Туре		Domain applies	-	•	Option(s)	update:	applicable)	Response Option(s)	Update
Туре	Domain	Domain applies	multiple times	аррисавіе	Hematologic	upuate.	applicable)	Hematologic Malignancy:	Opuate
					Malignancy: Acute			Acute myeloid leukemia	
					myeloid leukemia			(AML / ANLL), Acute	
					(AML / ANLL), Other			lymphoblastic leukemia	
					leukemia,			(ALL), Other leukemia,	
					Myelodysplastic			Myelodysplastic syndrome	
					syndrome (MDS),			(MDS), Myeloproliferative	
					Myeloproliferative			neoplasm (MPN),	
					neoplasm (MPN),			Overlapping myelodysplasia	
					Overlapping			/ myeloproliferative	
					myelodysplasia /			neoplasm (MDS / MPN),	
					myeloproliferative			Hodgkin lymphoma, Non-	
					neoplasm (MDS /			Hodgkin lymphoma,	
					MPN), Hodgkin			Multiple myeloma / plasma	
					lymphoma, Non-			cell neoplasms, Clonal	
					Hodgkin lymphoma,			cytogenetic abnormality	
					Clonal cytogenetic			without leukemia or MDS,	
					abnormality without			Uncontrolled proliferation	
					leukemia or MDS,			of donor cells without	
					Uncontrolled			malignant transformation.	
					proliferation of donor			Solid Tumors: Bone	
					cells without			sarcoma (regardless of	
					malignant			site), Soft tissue sarcoma	
	New Malignancy,				transformation			(regardless of site),	
	Lymphoproliferati				Solid Tumors:			Oropharyngeal cancer	
	ve or				Oropharyngeal			(e.g. tongue, mouth,	Be consistent with current clinical
Subsequent	Myeloproliferative			Specify the new	cancer (e.g. tongue,	Change/Clarification of		throat), Gastrointestinal	landscape, improve transplant outcome
Neoplasms	Disease / Disorder	yes	yes	malignancy	mouth, throat),	Response Options	Specify the new malignancy	malignancy (e.g.	data
	N N. 4 - 1.								
	New Malignancy,								
	Lymphoproliferati						Mas nost transplant		Be consistent with current clinical
Cubcoguest	ve or Myeloproliferative					Addition of Information	Was post-transplant		
Subsequent			NO.			Addition of Information	lymphoproliferative disorder	No Vos	landscape, improve transplant outcome
Neoplasms	Disease / Disorder	yes	yes			Requested	(PTLD) diagnosed?	No,Yes	data

	Domain Additional Sub	Response required if Additional Sub Domain applies	Collection may be requested	Element (if	Current Information Collection Data Element Response Option(s)	Information Collection update:	Proposed Information Collection Data Element (if applicable)	Proposed Information Collection Data Element Response Option(s)	Rationale for Information Collection Update
Subsequent Neoplasms	New Malignancy, Lymphoproliferati ve or Myeloproliferative Disease / Disorder	yes	yes			Addition of Information Requested	Specify type of PTLD	Monomorphic,Polymorphic, Unknown	Be consistent with current clinical landscape, improve transplant outcome data
Subsequent Neoplasms	New Malignancy, Lymphoproliferati ve or Myeloproliferative Disease / Disorder	ves	yes			Addition of Information Requested	Specify oropharyngeal cancer	Mouth,Throat,Tongue, Other oropharyngeal cancer	Be consistent with current clinical landscape, improve transplant outcome data
Subsequent Neoplasms	New Malignancy, Lymphoproliferati ve or Myeloproliferative Disease / Disorder		yes			Addition of Information Requested	Specify gastrointestinal malignancy	Anus,Colon,Esophagus,Liver ,Pancreas,Rectum,Small intestine (DUODENUM,	Be consistent with current clinical landscape, improve transplant outcome data
Subsequent Neoplasms	New Malignancy, Lymphoproliferati ve or Myeloproliferative Disease / Disorder	yes	yes			Addition of Information Requested	Specify genitourinary malignancy	Other genitourary	Be consistent with current clinical landscape, improve transplant outcome data
Subsequent	New Malignancy, Lymphoproliferati ve or Myeloproliferative Disease / Disorder		yes			Addition of Information Requested	Specify CNS malignancy	Glioma, Meningioma, Other CNS malignancy	Be consistent with current clinical landscape, improve transplant outcome data
Subsequent Neoplasms	New Malignancy, Lymphoproliferati ve or Myeloproliferative Disease / Disorder		yes			Addition of Information Requested	Was PTLD confirmed by biopsy?		Be consistent with current clinical landscape, improve transplant outcome data

	Domain Additional Sub	Response required if Additional Sub Domain applies	Collection may be requested	Element (if	Current Information Collection Data Element Response Option(s)	Information Collection update:	Proposed Information Collection Data Element (if applicable)	Proposed Information Collection Data Element Response Option(s)	Rationale for Information Collection Update
Subsequent Neoplasms	New Malignancy, Lymphoproliferati ve or Myeloproliferative Disease / Disorder	yes	yes			Addition of Information Requested	Was documentation submitted to the CIBMTR? (e.g. pathology report)	No,Yes	Be consistent with current clinical landscape, improve transplant outcome data
Subsequent Neoplasms	New Malignancy, Lymphoproliferati ve or Myeloproliferative Disease / Disorder	yes	yes			Addition of Information Requested	Was there EBV reactivation in the blood?	No,Not Done,Yes	Be consistent with current clinical landscape, improve transplant outcome data
Subsequent Neoplasms	New Malignancy, Lymphoproliferati ve or Myeloproliferative Disease / Disorder	yes	yes			Addition of Information Requested	How was EBV reactivation diagnosed?	Other method, Qualitative PCR of blood, Quantitative PCR of blood	Be consistent with current clinical landscape, improve transplant outcome data
Subsequent Neoplasms	New Malignancy, Lymphoproliferati ve or Myeloproliferative Disease / Disorder	yes	yes			Addition of Information Requested	Specify other method:	open text	Be consistent with current clinical landscape, improve transplant outcome data
Subsequent	New Malignancy, Lymphoproliferati ve or Myeloproliferative Disease / Disorder		yes			Addition of Information Requested	Quantitative EBV viral load of blood: At diagnosis	copies/ml	Be consistent with current clinical landscape, improve transplant outcome data
Subsequent Neoplasms	New Malignancy, Lymphoproliferati ve or Myeloproliferative Disease / Disorder		yes			Addition of Information Requested	Was a quantitative PCR of blood performed again after diagnosis?	No,Yes	Be consistent with current clinical landscape, improve transplant outcome data

Domain Sub-	Information Collection Domain Additional Sub Domain	Response required if Additional Sub Domain applies	Collection may be requested	Element (if	Collection Data Element Response	Information Collection update:	Proposed Information Collection Data Element (if applicable)	Proposed Information Collection Data Element Response Option(s)	Rationale for Information Collection Update
	New Malignancy, Lymphoproliferati ve or Myeloproliferative Disease / Disorder	yes	yes			Addition of Information Requested	Highest EBV viral load of blood:	copies/ml	Be consistent with current clinical landscape, improve transplant outcome data
· ·	New Malignancy, Lymphoproliferati ve or Myeloproliferative Disease / Disorder		yes			Addition of Information Requested	Was there lymphomatous involvement?	No,Yes	Be consistent with current clinical landscape, improve transplant outcome data
· ·	New Malignancy, Lymphoproliferati ve or Myeloproliferative Disease / Disorder	yes	yes			Addition of Information Requested	Specify sites of PTLD involvement (check all that apply)	Bone marrow, Central nervous system (brain or cerebrospinal fluid), Liver, Lung, Lymph node(s), Other, Spleen	Be consistent with current clinical landscape, improve transplant outcome data
	New Malignancy, Lymphoproliferati ve or Myeloproliferative Disease / Disorder		yes			Addition of Information Requested	Specify other site:	open text	Be consistent with current clinical landscape, improve transplant outcome data